Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 19;12:5049. doi: 10.1038/s41467-021-25175-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Heatmap summarising 59 prostate cancer PDXs established from 41 specimens obtained from 30 patients. The sample site, sample source, systemic therapies administered to patients prior to sample collection, clinical outcome at last follow-up, and pathology and biomarker expression of the PDXs are shown. Pathology of the PDXs was determined through histology review by pathologists and expression of phenotypic biomarkers by immunohistochemistry. NE marker staining indicates expression of ≥1 of chromogranin A, synaptophysin, and CD56. Immunohistochemistry results are from the latest PDX generation. *PDX 201.2A and PDX 201.2A-Cx are classified as adenocarcinoma based on pathology review and negative staining for synaptophysin and chromogranin A; however, they have focal staining of CD56. The naming convention for PDXs is a follows: numbers indicate patient ID and tumor site (e.g., 167.1 is patient 167, site 1), letters denote the sample source (R—radical prostatectomy; M—biopsy or surgical sample of metastasis; C— castration-resistant primary tissue; A—autopsy tissue), and Cx denotes subline grown in castrated mice.